| AQGNX | RWIHX | AQGNX / RWIHX | |
| Total Expense Ratio | 1.45 | 0.56 | 259% |
| Annual Report Gross Expense Ratio | 1.45 | 0.56 | 259% |
| Fund Existence | 17 years | 11 years | - |
| Gain YTD | 13.428 | 14.142 | 95% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 2500 | 250 | 1,000% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 628M | 158B | 0% |
| Annual Yield % from dividends | 0.98 | 1.51 | 65% |
| Returns for 1 year | 13.73 | 15.83 | 87% |
| Returns for 3 years | 48.67 | 45.00 | 108% |
| Returns for 5 years | 38.72 | 34.25 | 113% |
| Returns for 10 years | 101.01 | 95.72 | 106% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| ADGIX | 27.75 | 0.27 | +0.98% |
| AB Core Opportunities I | |||
| ACMVX | 16.91 | -0.04 | -0.24% |
| American Century Mid Cap Value Inv | |||
| NTKLX | 81.39 | -0.47 | -0.57% |
| Voya Multi-Manager International Sm Cp A | |||
| RYCEX | 102.96 | -0.62 | -0.60% |
| Rydex Europe 1.25x Strategy C | |||
| FPHAX | 33.73 | -0.28 | -0.82% |
| Fidelity Select Pharmaceuticals Port | |||